SUPN vs. KNSA, ARQT, INVA, OCUL, PHAT, PRGO, CORT, PCRX, NKTR, and OMER
Should you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Kiniksa Pharmaceuticals (KNSA), Arcutis Biotherapeutics (ARQT), Innoviva (INVA), Ocular Therapeutix (OCUL), Phathom Pharmaceuticals (PHAT), Perrigo (PRGO), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), and Omeros (OMER). These companies are all part of the "pharmaceutical preparations" industry.
Supernus Pharmaceuticals (NASDAQ:SUPN) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking.
Supernus Pharmaceuticals received 305 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 64.34% of users gave Kiniksa Pharmaceuticals an outperform vote.
In the previous week, Supernus Pharmaceuticals had 3 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 4 mentions for Supernus Pharmaceuticals and 1 mentions for Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 1.88 beat Supernus Pharmaceuticals' score of 0.97 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media.
Supernus Pharmaceuticals currently has a consensus price target of $41.00, indicating a potential upside of 51.18%. Kiniksa Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 63.07%. Given Kiniksa Pharmaceuticals' higher possible upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Supernus Pharmaceuticals.
54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Supernus Pharmaceuticals has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500.
Kiniksa Pharmaceuticals has a net margin of 2.78% compared to Supernus Pharmaceuticals' net margin of -2.60%. Supernus Pharmaceuticals' return on equity of -1.68% beat Kiniksa Pharmaceuticals' return on equity.
Kiniksa Pharmaceuticals has lower revenue, but higher earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Kiniksa Pharmaceuticals beats Supernus Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Supernus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Supernus Pharmaceuticals Competitors List
Related Companies and Tools
